BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10806842)

  • 21. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
    Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
    Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic and prognostic significance of serum soluble interleukin 2 receptor in children with malignancies].
    Bień E; Balcerska A; Ciesielski D
    Wiad Lek; 2006; 59(1-2):10-5. PubMed ID: 16646285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
    Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Concentration of soluble ligand for receptor CD30 (sCD30L)--marker of apoptosis in women with ovarian tumor].
    Mielczarek-Palacz A; Kondera-Anasz Z; Sikora J; Sodowski K; Switała J; Kubina R
    Ginekol Pol; 2009 Jul; 80(7):494-7. PubMed ID: 19697811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients.
    Yeo UC; Yang YS; Park KB; Sung HT; Jung SY; Lee ES; Shin MH
    J Dermatol Sci; 1999 Apr; 19(3):182-8. PubMed ID: 10215190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
    Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
    Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.
    Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
    Clin Exp Rheumatol; 2003; 21(1):63-9. PubMed ID: 12673891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors.
    Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Hauza G
    Hum Immunol; 2013 Jan; 74(1):70-4. PubMed ID: 23073297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
    Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
    Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma].
    Akiyama K; Tsuji M; Kurokawa Y; Yokota K; Kojima K; Naruo S; Kanayana HO; Kagawa S
    Nihon Hinyokika Gakkai Zasshi; 1997 Apr; 88(4):473-8. PubMed ID: 9155114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.
    Grutters JC; Fellrath JM; Mulder L; Janssen R; van den Bosch JM; van Velzen-Blad H
    Chest; 2003 Jul; 124(1):186-95. PubMed ID: 12853522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
    Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
    Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania.
    Tsai SY; Yang YY; Kuo CJ; Chen CC; Leu SJ
    J Affect Disord; 2001 May; 64(2-3):185-93. PubMed ID: 11313085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
    Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
    Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
    Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
    Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
    Ann Oncol; 1991 Feb; 2 Suppl 2():43-7. PubMed ID: 2049320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.